(NASDAQ: ENSC) Ensysce Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 19.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.24%.
Ensysce Biosciences's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast ENSC's revenue for 2026 to be $115,410,540, with the lowest ENSC revenue forecast at $110,884,637, and the highest ENSC revenue forecast at $118,804,968.
In 2027, ENSC is forecast to generate $1,308,720,847 in revenue, with the lowest revenue forecast at $1,257,392,986 and the highest revenue forecast at $1,347,220,416.